Sun Pharma gets USFDA nod to market generic Ethyol

New Delhi, Mar 17 (UNI) Sun Pharmaceutical Industries Ltd today said it has received USFDA approval to market a generic version of Medimmune's Ethyol amifostine injection used in cancer treatment.

Sun Pharma, being the first-to-file an Abbreviated New Drug Application (ANDA) for generic Ethyol, has a 180-day marketing exclusivity, a statement said.

This generic amifostine for injection, therapeutically equivalent to Medimmune's Ethyol amifostine injection of 500mg strength, is used as an adjuvant in cancer treatment. It will be used for reduction of kidney damage in patients who have advanced ovarian cancer and are being given repeat doses of cisplatin.

Ethyol has annual sales of about 80 million dollars in the US.

UNI SG SBA ND1245